Release Details


March 31, 2016

31 March 2016


LivaNova PLC (the “Company” or “LivaNova”) informs its shareholders that, on 31 March 2016, it filed an Amendment (“Form 8-K/A”) to its Current Report on Form 8-K originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on 19 October 2015. The Form 8-K/A can be found on the SEC’s website at

A copy of the Form 8-K/A has been submitted to the National Storage Mechanism on the date of this announcement and is, or will be, available for inspection at

About LivaNova

LivaNova PLC, headquartered in London, U.K., is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the U.K.’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN.”

For more information, please visit, or contact:

Investor Relations and Media
Karen King
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332


- End -